Oral Psoriasis Therapy ICOTYDE Sustains Response at Two Years

ICOTYDE, an investigational oral therapy for psoriasis, has held its results through the two-year mark, according to coverage by NewBeauty of the developer's announcement. That durability claim is the headline fact — and for a pill in this field, it's the fact that matters most.

Why? Because the oral psoriasis market is crowded with agents that work quickly and then raise long-term questions. Retention of effect at 24 months is the checkpoint where several once-promising oral candidates have stalled. A reported two-year signal, even in summary form, puts ICOTYDE in a smaller group.

What do we actually know so far?

The announcement, as reported by NewBeauty under the headline "Psoriasis Pill ICOTYDE Shows Lasting Results at 2 Years," states that the therapy demonstrated lasting results at two years. The coverage did not publish the underlying trial metrics — no PASI 75 or PASI 100 response rates, no head-to-head comparison against biologics, no safety discontinuation figures.

What's confirmed:

• ICOTYDE is an oral therapy — a pill, not an injectable biologic.
• The indication is psoriasis.
• Reported results extend to the two-year mark.
• The data were surfaced via NewBeauty's reporting on the developer's announcement.

What's not yet public in this coverage:

• Effect sizes (PASI scores, clearance rates).
• Study design, cohort size, or follow-up protocol.
• Safety and tolerability data over the two-year window.
• Regulatory status or filing timeline.

What does this change for patients and clinicians?

Right now, it changes the watch list, not the prescription pad. ICOTYDE remains investigational; no approval has been announced. For dermatologists, the relevant context is durability: oral agents that maintain response at two years would offer a maintenance option for patients who decline or fail injectable biologics — a cohort that consistently runs 20–30% of the moderate-to-severe population in adherence studies.

For patients, an effective pill removes the injection barrier entirely. That's the practical question every new oral candidate raises, and two-year durability is the first serious answer to it.

The bar ICOTYDE has to clear

Current biologic therapy sets a high reference point, with long-term extension studies routinely reporting maintained high-response rates across multi-year windows in moderate-to-severe plaque psoriasis. Any oral challenger will need to show its own PASI-based durability and safety data in peer-reviewed form before it enters treatment conversations.

The two-year announcement signals the developer intends to make that case. Expect the full dataset — response rates, safety tables, and regulatory next steps — to follow as the data move from press summary to scientific presentation.

By Olivia Hart for Derm Field.